Literature DB >> 8689954

Biotransformation of amitriptyline by Cunninghamella elegans.

D Zhang1, F E Evans, J P Freeman, B Duhart, C E Cerniglia.   

Abstract

A fungal biotransformation system as an in vitro model for mammalian drug metabolism was investigated. Amitriptyline, a widely used antidepressant, was effectively biotransformed within 72 hr by the filamentous fungus, Cunninghamella elegans. Eight major metabolites in HPLC elution order (11-hydroxyamitriptyline N-oxide, 11-hydroxynortriptyline, 11-hydroxyamitriptyline, 10-hydroxyamitriptyline, 3-hydroxyamitriptyline, 2-hydroxyamitriptyline, nortriptyline, and amitriptyline N-oxide) were produced at estimated molar ratios of 2:1:10:0.6:0.1:1.2.5:0.5, respectively. These metabolites were isolated by HPLC and identified by UV/MS analyses, as well as NMR spectroscopic analysis for most of these metabolites. In some cases, they were also compared with authentic standards. Glucose, culture age, and substrate concentration significantly affected the extent of amitriptyline metabolism. Kinetic studies indicated that nortriptyline and 11-hydroxyamitriptyline were produced as initial major metabolites. The hydroxylated metabolite was excreted from mycelia, but amitriptyline and its N-demethylated metabolite, nortriptyline, were not. An 18O2 labeling experiment showed that the oxygen atoms in 11-hydroxyamitriptyline and 2-hydroxyamitriptyline were derived from molecular oxygen. The cytochrome P450 inhibitors SKF 525-A (1.5 mM), metyrapone (2.0 mM), and 1-aminobenzotriazole (1.0 mM) inhibited the biotransformations of amitriptyline by 50, 75, and 95%, respectively. A microsomal preparation was shown to catalyze the 11-hydroxylation of amitriptyline, which was inhibited by SKF 525-A and carbon monoxide. The similarities of amitriptyline metabolism in C. elegans and in humans and rats are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8689954

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Transformation of amoxapine by Cunninghamella elegans.

Authors:  J D Moody; D Zhang; T M Heinze; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  2000-08       Impact factor: 4.792

2.  Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans.

Authors:  Shimpei Watanabe; Unnikrishnan Kuzhiumparambil; My Ann Nguyen; Jane Cameron; Shanlin Fu
Journal:  AAPS J       Date:  2017-04-28       Impact factor: 4.009

3.  Fungal biotransformation of the antihistamine azatadine by Cunninghamella elegans.

Authors:  D Zhang; E B Hansen; J Deck; T M Heinze; J B Sutherland; C E Cerniglia
Journal:  Appl Environ Microbiol       Date:  1996-09       Impact factor: 4.792

4.  Biotransformation of bromhexine by Cunninghamella elegans, C. echinulata and C. blakesleeana.

Authors:  Aman K Dube; Maushmi S Kumar
Journal:  Braz J Microbiol       Date:  2016-12-05       Impact factor: 2.476

5.  The CYPome of the model xenobiotic-biotransforming fungus Cunninghamella elegans.

Authors:  William Palmer-Brown; Raúl Miranda-CasoLuengo; Kenneth H Wolfe; Kevin P Byrne; Cormac D Murphy
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

6.  1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology.

Authors:  Paul R Ortiz de Montellano
Journal:  Med Chem (Los Angeles)       Date:  2018-03-31

7.  In vitro metabolism of synthetic cannabinoid AM1220 by human liver microsomes and Cunninghamella elegans using liquid chromatography coupled with high resolution mass spectrometry.

Authors:  Shimpei Watanabe; Unnikrishnan Kuzhiumparambil; Shanlin Fu
Journal:  Forensic Toxicol       Date:  2018-05-24       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.